Otonomy (San Diego, CA) a clinical-stage biopharmaceutical company focused on, hearing and balance disorders such as Ménière’s disease, hearing loss, and tinnitus. closed a $38.5M Series B financing. Participants include Novo Ventures, RiverVest Venture Partners, Domain Associates and TPG Biotech.

Dicerna Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on the development RNAi-based therapeutics, closed a $25M Series B financing. Participants include Domain Associates, Oxford Bioscience Partners, Abingworth Management and Skyline Ventures.

ReVision Optics (Lake Forest, CA) a clinical-stage medical device company focused on a corneal inlay for presbyopia, closed a $35M Series D financing. Participants include ProQuest Investments, Domain Associates, Canaan Partners and InterWest Partners.

Veracyte (San Francisco, CA) a clinical-stage molecular diagnostics company focused on non-small cell lung cancer and thyroid cancers, closed a $28M Series B financing. Participants include Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech and Versant Ventures.

Sequent Medical (Aliso Viejo, CA) a development-stage medical device company focused on endovascular treatment of neurovascular disease conditions, closed a $15.6M Series B financing. Participants include Domain Associates, Versant Ventures and US Venture Partners.

Astute Medical (San Diego, CA) a development-stage diagnostic company focused on the identification and validation of protein biomarkers that can test for hospital acquired acute conditions like sepsis, kidney injury and abdominal pain, closed a $26.5M Series B financing. Participants include Domain Associates, Delphi Ventures, Johnson & Johnson Development Corp. and De Novo Ventures.

Achaogen (San Francisco, CA) a clinical-stage a biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat life-threatening, multi-drug resistant bacterial infections, closed a $56M Series C financing. Participants include Frazier Healthcare Ventures, Alta Partners, 5 AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and Wellcome Trust.

Tragara Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on selective biomarker for oncology, pain and inflammation therapeutics, closed a $5M Series B financing. Participants include Domain Associates, Mitsubishi Corp., Morgethaler Ventures, Oxford Bioscience Partners and ProQuest Investments.

Carticept (Alpharetta, GA) a near commercial-stage medical device company focused on a computer controlled infusion system for osteoarthritis and cartilage injuries, closed a $20M Series B financing. Participants include SonoSite, Domain Associates and New Enterprise Associates.

Syndax Pharmaceuticals (Waltham, MA) a clinical-stage pharmaceutical company focused on an HDAC inhibitor for solid tumors and hematological tumors, closed a $9M Series A financing, bringing the total round to $49M. Participants include Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures and Pappas Ventures.